ANTLER trial shows positive initial data for CB-010 anti-CD19 allogeneic CAR T-cell therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Initial results from the ANTLER phase I trial for CB-010 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) demonstrated a 100% overall response rate and 80% complete response rate in cohort 1 (n=5 evaluable). 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login